GlassScriptPhysician profile
Denver Miller
NPI 1326059254
$6,770.58
in general payments reported to CMS, 2019-2025
56 companies · $609 in 2025
The $609 reported for 2025 was more than what 82% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $678 · 2021: $864 · 2022: $761 · 2023: $1,121 · 2024: $1,303 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.00 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.00 | 2019-2025 | |
| Pfizer INC. | $861.28 | 2019-2025 | |
| Astellas Pharma US INC | $564.43 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $434.31 | 2019-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $371.47 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Allergan, INC. | $312.13 | 2019-2020 | |
| Novo Nordisk INC | $283.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.66 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $231.66 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $210.79 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $199.14 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $108.70 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $108.48 | 2019-2021 | |
| Horizon Therapeutics Plc | $80.68 | 2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $69.20 | 2019-2025 | Eliquis |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denver Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.